JERUSALEM, May 31- Approval for Israel- based Teva Pharmaceutical Industries' drug to treat the neurological disorder chorea has been held up by U.S. regulators seeking further blood studies, the company said on Tuesday. "The FDA has asked Teva to examine blood levels of certain metabolites," Teva said, adding that these molecule deposits are also found in subjects... » Read More
Markets held gains on Tuesday after reports showed US home prices stabilized and consumer confidence improved. What should investors expect in the New Year and how should they be positioned? Tobias Levkovich, chief U.S. equity strategist at Citigroup, shared his strategies.
When I blogged last week about GlaxoSmithKline using the word “suck” in its new Nicorette ad campaign I thought it would be a one and done thing.
Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.
Futures mostly shrugged off news that weekly unemployment claims hit their lowest level in 15 months, but stocks were still poised for a gain in a holiday-shortened session Thursday.
Plus, get calls on the BlackBerry outage, pharma, dividends and more.
I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.
It's New Year's resolution time, so it's no surprise to see a sudden increase in commercials and ads for stop-smoking products. Pfizer's been heavily pushing its challenged Chantix and the other day I saw a commercial for GlaxoSmithKline's Nicorette that nearly made my jaw drop.
As senators made their way to Capitol Hill this weekend, a confluence of meteorological conditions conspired to dump nearly two feet of snow on Washington, DC. Unlike the decisions being made under the Capitol dome, we’ll soon dig ourselves out from the mountains of snow.
Australian vaccine maker CSL said on Monday its pandemic H1N1 swine flu vaccine delivered a strong immune response after just one dose in children as young as 6 months
This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.
If you have had the misfortune to follow this debate as it grinds through the Senate, several thoughts come to mind.
There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.
We are almost halfway through the dollar rally, Robin Griffiths from Cazenove Capital said Monday. Griffiths sees stock markets "topping" in March next year.
I went to the beleaguered Genzyme manufacturing plant in Allston, MA yesterday to get briefed on what exactly happened/is happening there for background ahead of my interview today with the CEO.
I'm on Amtrak's Acela (the faster train) to Boston to do an exclusive interview tomorrow with Genzyme Chairman and CEO Henri Termeer. It'll be live on "Power Lunch" around 1:30p ET. I was planning on spending the train trip reading up on GENZ, but I got easily sidetracked by the Auxilium news.
Health officials are recalling hundreds of thousands of doses of swine flu vaccine after tests indicated they may not be potent enough to protect against the virus.
At the UN's Climate Summit in Copenhagen there's a lot of talk about reducing CO2 emissions. Coincidentally, the Danish capital is headquarters to Novo Nordisk, whose CEO is setting an example about cutting down on greenhouse gases in the environment.
I've never been to San Antonio. I've heard great things about it, especially the downtown and the river that runs through it, but haven't been able to check it out yet.
Analyst meetings are usually carefully scripted, dry affairs. It's strictly business and rarely, if ever, does an exec open up and get personal. In the first q and a session at today's Lilly analyst meeting, John Johnson, the head of the company's cancer drug unit and former CEO of ImClone, fielded a question about Erbitux.
On May 8th Dendreon announced an offering of nearly 11 million more shares. Seven months later, on December 8th, DNDN announced another offering, this time for 15 million shares.